

## Editorial

As the Journal enters its seventh year as a monthly publication with a substantial increase in the page budget, a number of changes will be apparent on glancing at the inside front cover of this issue. Following the untimely loss of our first Chairman, Dr 'Johnny' Johnson, as reported in the Barcelona Symposium issue (cf. *J. Pharm. Biomed. Anal.* 6(6-8) i-ii, 1988), Dr Derek H. Calam has joined the Editorial Team as Chairman of the Editorial Advisory Board. As Head of Chemistry Division at the National Institute for Biological Standards and Control, just outside London, Dr Calam is active as a member of the British Pharmacopoeia Commission where he chairs or advises a number of committees dealing with the specification and control of biological products. He also serves various international bodies, including the European Pharmacopoeia Commission and the WHO. Dr Calam brings to the rôle of Chairman of the Editorial Advisory Board a breadth of experience which will be of value as the journal develops to serve the wider biomedical community.

In recent months a new journal office has been established at the University of Kansas and we are delighted to welcome Dr Christopher M. Riley in his new rôle as our Editor in North America. He will be primarily responsible for handling all North American submissions to the journal, which will include commissioning reviews on topical themes (any suggestions will be welcome!) and spearheading the development of the journal in serving the needs of our Authors in North America. Dr Riley is backed up in this important work by Professor Tom C. O'Haver and two new Associate Editors (Dr John F. Stobaugh and Dr Terry D. Wilson), who we also welcome to the Editorial Team. With a major research commitment at the Kansas University Center for Bioanalytical Research, Dr Chris Riley is active in international meetings both in the USA and in Europe, and has a long association with the journal, having co-authored a paper in the first issue.

Coincidental with establishing our North American office, we have been invited to contribute a Special Symposium Session on "Advances in Pharmaceutical and Biomedical Analysis" at the 40th Pittsburgh Conference, to be held in the Georgia World Congress Center in Atlanta on 6-10 March 1989. This Symposium Session is scheduled for Monday 6 March (starting in customary US style at 8.30 a.m.!) and will cover a number of topical themes, including chiral separations in drug analysis, therapeutic drug monitoring in paediatrics, bioanalysis of anticancer drugs through to advances in computer-aided analysis. This is the first time that the journal has been invited to contribute in this way to a major international meeting and we are honoured to participate.

Readers of this journal will be aware of our long-standing and scientifically productive association with the Belgian Society of Pharmaceutical Sciences. Their next International Symposium on Drug Analysis will be held in Antwerp on 15-19 May 1989 and the Proceedings will be published in the current volume of the *Journal of Pharmaceutical and Biomedical Analysis* at the end of the year. This will be the third Belgian Symposium to

be held in a highly successful series — full details of which will be found in the end papers of this issue.

Looking a little further ahead to 1990, the next Symposium on Pharmaceutical and Biomedical Analysis will be held in the Roman city of York, UK, following the successful first meeting organized by Professor Emilio Gelpí in Barcelona in 1987. The York meeting is organized jointly with the Chromatographic Society, UK and promises to be another memorable event in the development of pharmaceutical analysis at the international level. The active participation of all our authors and readers will be welcomed. Full details can be found elsewhere in this issue.

Finally, we welcome a number of new members to the Editorial Advisory Board and take the opportunity to thank those Board members whose term of office ended in 1988. To them and to the large number of scientists who give generously of their time and expertise to review articles, we extend our sincere thanks, as the journal enters a new phase in its international development.

Anthony F. Fell